High-Risk Human Papillomavirus DNA in the Primary Tumor, Sentinel, and Nonsentinel Pelvic Lymph Nodes in Patients With Early-Stage Cervical Cancer A Correlation With Histopathology

被引:15
作者
Slama, Jiri [3 ]
Drazdakova, Marcela [1 ]
Dundr, Pavel [2 ]
Fischerova, Daniela
Zikan, Michal
Pinkavova, Ivana
Freitag, Pavel
Pavlista, David
Zima, Tomas [1 ]
Cibula, David
机构
[1] Charles Univ Prague, Inst Clin Biochem & Lab Diagnost, Sch Med 1, Prague 12851 2, Czech Republic
[2] Charles Univ Prague, Dept Pathol, Sch Med 1, Prague 12851 2, Czech Republic
[3] Charles Univ Prague, Gen Teaching Hosp, Dept Oncogynecol, Sch Med 1, Prague 12851 2, Czech Republic
关键词
Cervical cancer; HPV; Lymph node; Sentinel lymph node; Recurrence; HPV DNA; PROGNOSTIC-SIGNIFICANCE;
D O I
10.1111/IGC.0b013e3181a13186
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Metastatic involvement of pelvic lymph nodes is the most important prognostic parameter in early-stage cervical cancer. Still, approximately 15% of patients with negative pelvic nodes experience recurrence, most of them in the pelvis. The presence of human papillomavirus (HPV) DNA in histologically negative pelvic nodes is considered a subclinical metastatic spread. Methods: Patients with early-stage cervical cancer referred for surgical treatment were enrolled in the study. Cytobrush technique was used for sample collection from the fresh tissue to avoid any loss of material for histology. Results: Altogether, 49 patients were enrolled in the study. High-risk (HR) HPV DNA was identified in the tumor in 91.8% patients and in the sentinel node or other pelvic nodes in 49.9% patients. Among the 10 HR HPV genotypes detected, HPV 16 was the most frequently represented in both the tumor and the lymph nodes (66.7% and 7 1.4%, respectively). All metastatic lymph nodes were HR HPV positive. Conclusions: The presence of HR HPV DNA in a sentinel node had a 100% positive predictive value for metastatic involvement of pelvic lymph nodes in Our study. This could be considered a sign of an early subclinical metastatic spread; however, the prognostic value has to be evaluated through a longer follow-up.
引用
收藏
页码:703 / 707
页数:5
相关论文
共 22 条
[1]   Detection of HPV-16 DNA by PCR in histologically cancer free lymph nodes from patients with cervical cancer [J].
Baay, MFD ;
Koudstaal, J ;
Hollema, H ;
Duk, JM ;
Burger, MPM ;
Quint, WGV ;
Stolz, E ;
Herbrink, P .
JOURNAL OF CLINICAL PATHOLOGY, 1997, 50 (11) :960-961
[2]   Histopathological validation of the sentinel node concept in cervical cancer [J].
Barranger, E ;
Cortez, A ;
Commo, F ;
Marpeau, O ;
Uzan, S ;
Darai, E ;
Callard, P .
ANNALS OF ONCOLOGY, 2004, 15 (06) :870-874
[3]   Laparoscopic sentinel node procedure for cervical cancer: Impact of neoadjuvant chemoradiotherapy [J].
Barranger, E ;
Cortez, A ;
Grahek, D ;
Callard, P ;
Uzan, S ;
Darai, E .
ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (04) :445-452
[4]  
Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209
[5]   Detection and quantitation of human papillomavirus DNA in primary tumour and lymph nodes of patients with early stage cervical carcinoma [J].
Chan, PKS ;
Yu, MMY ;
Cheung, TH ;
To, KF ;
Lo, KWK ;
Cheung, JLK ;
Tong, JHM .
JOURNAL OF CLINICAL VIROLOGY, 2005, 33 (03) :201-205
[6]   Human papillomavirus types in invasive cervical cancer worldwide:: a meta-analysis [J].
Clifford, GM ;
Smith, JS ;
Plummer, M ;
Muñoz, N ;
Franceschi, S .
BRITISH JOURNAL OF CANCER, 2003, 88 (01) :63-73
[7]   Frequency and prognostic significance of HPV DNA in sentinel lymph nodes of patients with cervical cancer [J].
Coutant, C. ;
Barranger, E. ;
Cortez, A. ;
Dabit, D. ;
Uzan, S. ;
Bernaudin, J. F. ;
Darai, E. .
ANNALS OF ONCOLOGY, 2007, 18 (09) :1513-1517
[8]   CAN A TEST FOR E6/E7 TRANSCRIPTS OF HUMAN PAPILLOMAVIRUS TYPE-16 SERVE AS A DIAGNOSTIC-TOOL FOR THE DETECTION OF MICROMETASTASIS IN CERVICAL-CANCER [J].
CZEGLEDY, J ;
IOSIF, C ;
HANSSON, BG ;
EVANDER, M ;
GERGELY, L ;
WADELL, G .
INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (03) :211-215
[9]   Prognostic significance of high-risk HPV status in advanced cervical cancers and pelvic lymph nodes [J].
Füle, T ;
Csapó, Z ;
Máthé, M ;
Tátrai, M ;
László, V ;
Papp, Z ;
Kovalszky, I .
GYNECOLOGIC ONCOLOGY, 2006, 100 (03) :570-578
[10]  
Hernádi Z, 2003, BJOG-INT J OBSTET GY, V110, P205, DOI 10.1016/S1470-0328(02)01916-X